Safety and pharmacokinetics of idelalisib in subjects with renal impairments and healthy volunteers

Trial Profile

Safety and pharmacokinetics of idelalisib in subjects with renal impairments and healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2016

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Pancreatic cancer; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 11 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top